Andere Sprachen Zentalis Pharmaceuticals, Inc.

Aktien

A2P209

US98943L1070

ZNTL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 06.05.2024			% 5 Tage	% 1. Jan.
11,72 ^USD	+0,09 %		+2,63 %	-22,64 %

11.04.	Zentalis Pharmaceuticals, Inc. kündigt Änderungen in der Geschäftsführung an	CI
02.04.	Zentalis Pharmaceuticals stellt auf der AACR-Jahrestagung 2024 präklinische Daten vor, die zeigen, dass der Wee1-Inhibitor Azenosertib eine synergistische Anti-Tumor-Aktivität mit Kras(G12c)-Inhibitoren aufweist	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.05.
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	11.04.
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	11.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024	03.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024	02.04.
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	02.04.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.04.
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	04.03.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.03.
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences	28.02.
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates	27.02.
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference	13.02.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.02.
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	25.01.
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments	25.01.
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	25.01.
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	08.01.
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	03.01.
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zentalis Pharmaceuticals, Inc.

Aktien

A2P209

US98943L1070

ZNTL

Andere Sprachen

Filter